Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 4Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 13Carcinoma, Hepatocellular 8Nasopharyngeal Carcinoma 6Esophageal Neoplasms 6Neoplasm Metastasis 5Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Melanoma 4Advanced NSCLC 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Rectal Neoplasms 3Pancreatic Neoplasms 3Small Cell Lung Carcinoma 2Sarcoma 2Neoplasms 2Lung Neoplasms 2Locally Advanced Rectal Cancer 2Leukemia, Myeloid, Acute 2Esophageal Squamous Cell Carcinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Biliary Tract Neoplasms 2Advanced Solid Tumors 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1

Interventions

Gemcitabine 24Cisplatin 24durvalumab 13pembrolizumab 9Oxaliplatin 7Capecitabine 7Fluorouracil 6Leucovorin 5Bevacizumab 5lenvatinib 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4Nivolumab 3Liquid Biopsy 3Injections 3Folfox protocol 3Carboplatin 3zanidatamab 2trifluridine tipiracil drug combination 2tremelimumab 2tislelizumab 2ivosidenib 2futibatinib 2apatinib 2Trastuzumab 2Taxes 2Irinotecan 2Immune Checkpoint Inhibitors 2Drug Therapy 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Biliary Tract Neoplasms × Immune Checkpoint Inhibitors × Clear all
NCT07466238 2026-05-08

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Peking University

Phase NA Recruiting
40 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT07282262 2025-12-15

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Peking Union Medical College Hospital

Phase 2 Recruiting
300 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡